NCT07378046

The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster

The Analgesic Efficacy and Safety of Oral Medications (Baclofen) in Patients With Herpes Zoster

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 750 (estimated)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the potential role of muscle relaxant, which can relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions. Therefore, investigators hypothesize that baclofen may effectively reduce the severity of HZ pain without significantly increasing adverse events.

Conditions

• Herpes Zoster
• Pain

Interventions

Type	Name	Description
DRUG	Baclofen combined conventional therapy	In the baclofen combined conventional therapy group, baclofen will be initiated at 15 mg daily. Then, based on the patient's response, the single dose can be gradually increased by 5mg each time, with a three-day interval. The maximum recommended dose is 30\~75mg daily. In addition, the group will contain conventional treatment for HZ, except baclofen, including NSAIDs, opioids, antiviral drugs and so on.
DRUG	Conventional therapy	In the conventional therapy group, treatments will include NSAIDs, opioids, antiviral drugs and so on.

Timeline

• Start date: 2025-12-15
• Primary completion: 2027-09-30
• Completion: 2027-12-31
• First posted: 2026-01-30
• Last updated: 2026-01-30

Locations

1 site across 1 country: China